Biotech and academic researchers harness artificial intelligence to unravel genetic networks and streamline drug discovery. Northwestern University developed TWAVE, an AI tool identifying gene combinations underpinning complex diseases. Separately, Juvenescence acquired AI drug discovery firm Ro5 to bolster AI-driven therapeutics targeting aging. Additionally, a collaborative open-source AI model, Boltz-2, predicts small molecule-protein binding affinity with improved accuracy, aiming to accelerate drug development pipelines.